Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.
about
Progress in Metabolomics Standardisation and its Significance in Future Clinical Laboratory MedicineMetabolomics combined with pattern recognition and bioinformatics analysis methods for the development of pharmacodynamic biomarkers on liver fibrosis.Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.Multifocal demyelinating motor neuropathy and hamartoma syndrome associated with a de novo PTEN mutation.
P2860
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Plasma Metabolomic Changes fol ...... y to Phase I Trial Evaluation.
@en
Plasma Metabolomic Changes fol ...... y to Phase I Trial Evaluation.
@nl
type
label
Plasma Metabolomic Changes fol ...... y to Phase I Trial Evaluation.
@en
Plasma Metabolomic Changes fol ...... y to Phase I Trial Evaluation.
@nl
prefLabel
Plasma Metabolomic Changes fol ...... y to Phase I Trial Evaluation.
@en
Plasma Metabolomic Changes fol ...... y to Phase I Trial Evaluation.
@nl
P2093
P2860
P1476
Plasma Metabolomic Changes fol ...... y to Phase I Trial Evaluation.
@en
P2093
Alan T Henley
Alexis de Haven Brandon
Bart Vanhaesebroeck
Johann S de Bono
Joo Chew Ang
Joo Ern Ang
Lori Friedman
Melanie Valenti
Mika Derynck
P2860
P304
P356
10.1158/1535-7163.MCT-15-0815
P577
2016-04-05T00:00:00Z